Abstract: Ｏｂｊｅｃｔｉｖｅ：The purpose of this study was to explore the efficacy of chrysin(CHR) on lupus nephritis (LN) and its effects on interleukin6（IL6）／signaling protein and transcriptional activator 3(STAT3) based on the clinically effective “multitarget” therapy and its early efficacy mechanism signaling pathway. 
Ｍｅｔｈｏｄｏｌｏｇｙ：We randomly divided 10weekold MRL／lpr lupus mice into disease group and CHRtreated group. C57BL／6 mice were used as normal control (NC), with 6 mice in each group. The CHR group was given CHR 160 mg／（kg·d） by gavage, the MRL／lpr group and NC group were given the same amount of carboxymethylcellulose sodium (CMCNa) by gavage, and all the mice were sacrificed after continuous administration for 8 weeks. The spleen and renal tissue of mice in different groups were collected for testing. The spleen weight and the spleen index were evaluated. And the pathological changes of kidney tissue were observed by PAS staining; ELISA was performed to detect the urine protein／creatinine level and the serum interleukin6 (IL6) level; IL6 mRNA and PSTAT3 protein expressions in kidney was evaluated by qPCR、western blot and IHC staining.
Ｒｅｓｕｌｔｓ：Our results found that CHR treatment could alleviate spleen weight and spleen index. Furthermore, CHR can downregulate urinary protein／creatinine levels as well as the pathological damage of renal tissue. The circulating IL6 secretion levels and IL6、pSTAT3 expressions in kidney were also inhibited by CHR.
Ｃｏｎｃｌｕｓｉｏｎ：In conclusion, our work found that CHR may have a protective effect in MRL／lpr lupus mice by inhibiting IL6／STAT3 signaling, providing a reference for the development of new LN drugs.

Key words: chrysin,lupus nephritis,interleukin-6